Pulmatrix (NASDAQ: PULM) said today that it has received a key patent in the United States for its lead drug candidate, PUR0200, which is intended to treat chronic obstructive pulmonary diseases (COPD). PUR0200 is an inhaled drug made by combining Pulmatrix’s technology platform with tiotropium bromide. The patent provides the company with intellectual property protection for the drug until 2033. The company is currently developing PUR0200 in both Europe and the United States, following regulatory pathways that offer faster approvals and decreased costs. “This new patent is another step forward to bringing PUR0200 to market—and to be able to offer new benefits to patients suffering from COPD,” Robert W. Clarke, Ph.D., Pulmatrix CEO, stated in the news release.
To view the full press release, visit: http://nnw.fm/GXVp8
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The company’s proprietary product pipeline is focused on advancing treatments for lung diseases, including opportunities in major pulmonary diseases through collaborations, like PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) and PUR1900, an inhaled antifungal that could benefit severe asthmatics and patients with rare diseases like cystic fibrosis. Pulmatrix’s product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. For more information, visit www.pulmatrix.com.
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer